EMA Publishes New Guidelines For Certain Medical Devices

Author:Singh & Associates
Profession:Singh & Associates
 
FREE EXCERPT

On February 28, 2019, European Medicine Agency (EMA) (hereafter referred as 'Agency') published the first guidance on new rules for certain medical devices - the first of a series of guidance documents to help applicants to prepare for compliance with these new rules. The first guidance introduces new roles and responsibilities for EMA and national competent authorities (NCAs) in relation to certain types of medical devices and in-vitro diagnostics, demands efforts from the Agency with stakeholders including pharmaceutical and medical device industries, and notified bodies, to ensure a smooth transition to the new regulatory framework.

The new guidance document has been developed jointly by EMA and the Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh) in close collaboration with the European Commission.

Key points of new guidelines

This guidance document is prepared for the applicants to help them understand the scope of the Agency, its activities and should be read in conjunction with the new medical devices Regulation (EU) 2017/745, and the new In-vitro Diagnostic Medical Devices Regulation (EU) 2017/746. These regulations lay down roles and responsibilities for EMA and National Competent Authorities (NCA) for medicines, as follows:

For medical devices incorporating a medicinal substance (with action ancillary to the device) the notified body shall seek a scientific opinion from either the NCAs or EMA. The notified body shall seek the opinion of EMA for medicinal products falling exclusively within the scope of centralized procedure, or those that incorporate human blood or plasma derivatives. For devices that are composed of substances or of combinations of substances that are systemically absorbed by the body in order to achieve their intended purpose, the notified body shall seek a scientific...

To continue reading

REQUEST YOUR TRIAL